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The Human Side of Diabetes Care
O
n behalf of our outstanding team
of associate editors, I am honored
andprivilegedtoreporttoyouthe
current state of Diabetes Care at the end
ofthethirdyearofourtenure.Thejour-
nal continues to enjoy a wide interna-
tional readership and a high impact
factor that allows us to be ranked fourth
out of 92 journals in diabetes and endo-
crinology and tenth out of 100 general
medicine journals. Though we are
clearly making progress in clinical sci-
ence,Iwanttohighlightourchallenges,
particularlyinthehumanisticaspectsof
diabetes, as we contribute to the mis-
sion of not only ﬁnding a cure for the
disease but also improving the lives of
people with diabetes.
The explosion of interest in the ﬁeld
of diabetes and its comorbidities, along
with increased research, has enabled
maintenance of the record submission
rate established about 2 years ago. This
rate seems to have plateaued a bit, per-
haps because of frustration with our
high rejection rate, which is currently
75%. Regrettably, space constraints of-
ten dictate the rejection of many well-
done studies, a portion of which the
editorial committee is forced to return
without external review, thus present-
ing the difﬁcult task of disappointing
authors. I would like to emphasize that
this does not mean that the study has
notbeenreadinternallybyourassociate
editors.Theadvantagetoauthorsisthat
they will at least get the “bad news”
quickly rather than waiting for several
weeks. Having said that, our overall
time to initial decision continues to fall
and is currently at a median of 13 days,
thanks to our excellent and continually
improving online submission system.
Again, I would like to remind readers
and authors of their responsibility to re-
view papers—without which the peer
review system would fail.
The plateauing of the submission
rate may have a disturbing implication:
the amount of diabetes research is not
increasing in line with the increase in
the prevalence and importance of the
disease. It is vital that we continue to
pressure grant-giving bodies to fund re-
search in diabetes and encourage young
investigatorstocontinueinanacademic
career and build the next generation of
leaders in the ﬁeld. I am delighted with
the recent changes in the research poli-
cies of the American Diabetes Associa-
tion (ADA), which will encourage and
enhance clinical and translational re-
search. In this issue of Diabetes Care,w e
publish an editorial on this important
topic by Dr. Paul Robertson, ADA Pres-
ident, Science and Medicine. Given the
importance of research funding, we
plan to acknowledge the support of re-
search grantors appropriately and
would particularly like to highlight re-
search that is funded by the ADA, al-
though such papers in no way receive
any preference or priority in the review
process.
The last year has seen the publication
and presentation of several landmark
clinical trials reporting on goals for meta-
bolic control and how these goals should
be achieved, which has stirred up much
controversy. We are pleased to publish
the ADA’s response to these controver-
sies, which has been developed jointly
with organizations such as the American
Heart Association and others. We wel-
come the collaboration across specialty
lines that is important in overcoming the
complex multisystem complications of
diabetes.
Much progress continues to be
made in new developments in the phar-
maceutical industry in therapy for dia-
betes. We encourage such research but
point out that Diabetes Care can only
publish studies that address novel con-
cepts rather than repetitive “me too”
clinical trials—even if they are well
done and up to the standards of the
Food and Drug Administration. We
would rather publish clinical trials that
are likely to change clinical practice in a
broader sense. Thus, many otherwise
well-conducted trials will not be pub-
lished in our journal. I would also like
to take the opportunity to remind spon-
sorsofclinicaltrialsoftheobligationsof
authorship, which are well known and
were published and highlighted in my
editorial last year. We hope that guide-
lines from the Accreditation Council for
Continuing Medical Education and the
International Committee of Medical
Journal Editors will continue to be re-
ﬁned and fully implemented. We also
continue to implement the requirement
that all clinical trials be registered, in-
cluding nonpharmacological interven-
tions. We encourage complete
transparency of the data from clinical
trials, particularly adverse events and
patient dropout. This may be achieved
by including details such as a Consoli-
dated Standards of Reporting Trials
(CONSORT) statement, which we en-
courage but do not mandate. To save
spaceintheprintedition,suchinforma-
tion can now be included for online
publication only and referred to in the
textofthemainpaper.Shortly,theADA
will partner with other international or-
ganizationstodevelopguidelinesonthe
typeofresearchthatwefeelisneededto
achieve our mission. We hope that we
can reach consensus on the most clini-
cally useful and ethical approach to
research.
We continue to have important de-
bates on health care policies and
changes that we hope will improve the
care of people with chronic disease,
such as those with diabetes. Again, the
ADA is taking major initiatives in advo-
cacy for improvements in health care
policy,whichweplantopublishshortly
as a commentary. We look forward to
continuing debate and suggestions as
we attempt to improve the lives of peo-
ple with diabetes and as we move along
toward ﬁnding a cure.
While we attempt to ﬁnd a cure for
diabetes, I would like to highlight the
human side of living with the disease,
and I chose to put on the cover of this
month’s issue a letter to the Insulin Dis-
covery Team and Dr. Banting from the
grandmother of one of our own associ-
ate editors, Lois Jovanovic. It illustrates
the gratitude and emotion that she must
have felt when a “cure” was found for
what was then a life-threatening dis-
ease. We welcome letters and anecdotes
that highlight success in dealing with
diabetes. We hope the day is not too
distant when we can offer similar hope
to all of the millions of people who suf-
fer with diabetes on a chronic basis.
Iwouldliketotakethisopportunity
to thank our outstanding team of asso-
ciate editors and to bid farewell to Lois
Jovanovic after her many years of out-
standing service to the journal in gen-
eral and to the cause of women with
diabetes in particular. (See the online
letter available at http://dx.doi.org/10.
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step down and make way for Dr. Robert
Moses from Australia, who brings an-
other dimension to our expansion and
recognitionasatrulyinternationaljour-
nal. We also welcome the new members
of the editorial board and thank our
outgoing members (Jonathan Shaw,
Richard Pratley, David Leslie, Joshua
Barzilay, Bruce Duncan, David Ludwig,
Martha Price, and Carolyn Blue) for
their expert service.
Finally, nothing would be accom-
plished without the hard work and ded-
icationofourofﬁcestaff,Lyn,Shannon,
and Jane, who put in long hours assist-
ing authors and reviewers alike and
have been able to successfully incorpo-
rate the added responsibilities that
electronic submission and quality pub-
lication incur. All this leads to contin-
ued recognition of Diabetes Care as the
leading journal in diabetes, publishing
papers of clinical, public health, and
humanistic importance.
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